19 results on '"Philipson, Casandra W."'
Search Results
2. Author Correction: Detection of COVID-19 using multimodal data from a wearable device: results from the first TemPredict Study
- Author
-
Mason, Ashley E., Hecht, Frederick M., Davis, Shakti K., Natale, Joseph L., Hartogensis, Wendy, Damaso, Natalie, Claypool, Kajal T., Dilchert, Stephan, Dasgupta, Subhasis, Purawat, Shweta, Viswanath, Varun K., Klein, Amit, Chowdhary, Anoushka, Fisher, Sarah M., Anglo, Claudine, Puldon, Karena Y., Veasna, Danou, Prather, Jenifer G., Pandya, Leena S., Fox, Lindsey M., Busch, Michael, Giordano, Casey, Mercado, Brittany K., Song, Jining, Jaimes, Rafael, Baum, Brian S., Telfer, Brian A., Philipson, Casandra W., Collins, Paula P., Rao, Adam A., Wang, Edward J., Bandi, Rachel H., Choe, Bianca J., Epel, Elissa S., Epstein, Stephen K., Krasnoff, Joanne B., Lee, Marco B., Lee, Shi-Wen, Lopez, Gina M., Mehta, Arpan, Melville, Laura D., Moon, Tiffany S., Mujica-Parodi, Lilianne R., Noel, Kimberly M., Orosco, Michael A., Rideout, Jesse M., Robishaw, Janet D., Rodriguez, Robert M., Shah, Kaushal H., Siegal, Jonathan H., Gupta, Amarnath, Altintas, Ilkay, and Smarr, Benjamin L.
- Published
- 2022
- Full Text
- View/download PDF
3. Identification of new regulatory genes through expression pattern analysis of a global RNA-seq dataset from a Helicobacter pylori co-culture system
- Author
-
Tubau-Juni, Nuria, Bassaganya-Riera, Josep, Leber, Andrew, Zoccoli-Rodriguez, Victoria, Kronsteiner, Barbara, Viladomiu, Monica, Abedi, Vida, Philipson, Casandra W., and Hontecillas, Raquel
- Published
- 2020
- Full Text
- View/download PDF
4. Direct-from-blood RNA sequencing identifies the cause of post-bronchoscopy fever
- Author
-
Ko, Emily R., Philipson, Casandra W., Burke, Thomas W., Cer, Regina Z., Bishop-Lilly, Kimberly A., Voegtly, Logan J., Tsalik, Ephraim L., Woods, Christopher W., Clark, Danielle V., and Schully, Kevin L.
- Published
- 2019
- Full Text
- View/download PDF
5. Early Identification of the SARS-CoV-2 Omicron BA.2.86 Variant by the Traveler-Based Genomic Surveillance Program--Dulles International Airport, August 2023
- Author
-
Bart, Stephen M., Rothstein, Andrew P., Philipson, Casandra W., Smith, Teresa C., Simen, Birgitte B., Tamin, Azaibi, Atherton, Lydia J., Harcourt, Jennifer L., Walker, Allison Taylor, Payne, Daniel C., Ernst, Ezra T., Morfino, Robert C., Ruskey, Ian, and Friedman, Cindy R.
- Subjects
Travelers -- Health aspects ,Airports -- Health aspects ,Health - Abstract
During August 13-14, 2023, a new SARS-CoV-2 Omicron subvariant with a large number of mutations compared with previously circulating BA.2 variants (>30 amino acid differences in its spike protein) was [...]
- Published
- 2023
6. Genomic Characterization of a Relative of Mumps Virus in Lesser Dawn Bats of Southeast Asia.
- Author
-
Paskey, Adrian C., Lim, Xiao Fang, Ng, Justin H. J., Rice, Gregory K., Chia, Wan Ni, Philipson, Casandra W., Foo, Randy, Cer, Regina Z., Long, Kyle A., Lueder, Matthew R., Glang, Lindsay, Frey, Kenneth G., Hamilton, Theron, Mendenhall, Ian H., Smith, Gavin J., Anderson, Danielle E., Wang, Lin-Fa, and Bishop-Lilly, Kimberly A.
- Subjects
MUMPS ,RNA replicase ,BATS ,COVID-19 pandemic ,RNA polymerases - Abstract
The importance of genomic surveillance on emerging diseases continues to be highlighted with the ongoing SARS-CoV-2 pandemic. Here, we present an analysis of a new bat-borne mumps virus (MuV) in a captive colony of lesser dawn bats (Eonycteris spelaea). This report describes an investigation of MuV-specific data originally collected as part of a longitudinal virome study of apparently healthy, captive lesser dawn bats in Southeast Asia (BioProject ID PRJNA561193) which was the first report of a MuV-like virus, named dawn bat paramyxovirus (DbPV), in bats outside of Africa. More in-depth analysis of these original RNA sequences in the current report reveals that the new DbPV genome shares only 86% amino acid identity with the RNA-dependent RNA polymerase of its closest relative, the African bat-borne mumps virus (AbMuV). While there is no obvious immediate cause for concern, it is important to continue investigating and monitoring bat-borne MuVs to determine the risk of human infection. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Animal models of enteroaggregative Escherichia coli infection
- Author
-
Philipson, Casandra W., Bassaganya-Riera, Josep, and Hontecillas, Raquel
- Published
- 2013
8. The temporal RNA virome patterns of a lesser dawn bat (Eonycteris spelaea) colony revealed by deep sequencing.
- Author
-
Paskey, Adrian C, Ng, Justin H J, Rice, Gregory K, Chia, Wan Ni, Philipson, Casandra W, Foo, Randy J H, Cer, Regina Z, Long, Kyle A, Lueder, Matthew R, Frey, Kenneth G, Hamilton, Theron, Mendenhall, Ian H, Smith, Gavin J, Wang, Lin-Fa, and Bishop-Lilly, Kimberly A
- Subjects
RNA ,BATS as carriers of disease ,NUCLEOTIDE sequencing ,SHOTGUN sequencing ,ZOONOSES - Abstract
The virosphere is largely unexplored and the majority of viruses are yet to be represented in public sequence databases. Bats are rich reservoirs of viruses, including several zoonoses. In this study, high throughput sequencing (HTS) of viral RNA extracted from swabs of four body sites per bat per timepoint is used to characterize the virome through a longitudinal study of a captive colony of fruit nectar bats, species Eonycteris spelaea in Singapore. Through unbiased shotgun and target enrichment sequencing, we identify both known and previously unknown viruses of zoonotic relevance and define the population persistence and temporal patterns of viruses from families that have the capacity to jump the species barrier. To our knowledge, this is the first study that combines probe-based viral enrichment with HTS to create a viral profile from multiple swab sites on individual bats and their cohort. This work demonstrates temporal patterns of the lesser dawn bat virome, including several novel viruses. Given the known risk for bat–human zoonoses, a more complete understanding of the viral dynamics in South-eastern Asian bats has significant implications for disease prevention and control. The findings of this study will be of interest to U.S. Department of Defense personnel stationed in the Asia-Pacific region and regional public health laboratories engaged in emerging infectious disease surveillance efforts. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. NLRX1 suppresses tumorigenesis and attenuates histiocytic sarcoma through the negative regulation of NF-κB signaling
- Author
-
Philipson, Casandra W., Coutermarsh-Ott, Sheryl, Ting, Jenny P-Y, Dervisis, Nikolaos, LeRoith, Tanya, Heid, Bettina, Capria, Vittoria, Bassaganya-Riera, Josep, Hontecillas-Magarzo, Raquel, Allen, Irving C., Qin, Qizhi, Wilson, Justin E., and Simmons, Alysha
- Abstract
Histiocytic sarcoma is an uncommon malignancy in both humans and veterinary species. Research exploring the pathogenesis of this disease is scarce; thus, diagnostic and therapeutic options for patients are limited. Recent publications have suggested a role for the NLR, NLRX1, in acting as a tumor suppressor. Based on these prior findings, we hypothesized that NLRX1 would function to inhibit tumorigenesis and thus the development of histiocytic sarcoma. To test this, we utilized Nlrx1−/− mice and a model of urethane-induced tumorigenesis. Nlrx1−/− mice exposed to urethane developed splenic histiocytic sarcoma that was associated with significant up-regulation of the NF-λB signaling pathway. Additionally, development of these tumors was also significantly associated with the increased regulation of genes associated with AKT signaling, cell death and autophagy. Together, these data show that NLRX1 suppresses tumorigenesis and reveals new genetic pathways involved in the pathobiology of histiocytic sarcoma.
- Published
- 2016
- Full Text
- View/download PDF
10. Modeling the Regulatory Mechanisms by Which NLRX1 Modulates Innate Immune Responses to Helicobacter pylori Infection.
- Author
-
Philipson, Casandra W., Bassaganya-Riera, Josep, Viladomiu, Monica, Kronsteiner, Barbara, Abedi, Vida, Hoops, Stefan, Michalak, Pawel, Kang, Lin, Girardin, Stephen E., and Hontecillas, Raquel
- Subjects
- *
NATURAL immunity , *HELICOBACTER pylori infections , *HEALTH outcome assessment , *MACROPHAGES , *PATTERN perception - Abstract
Helicobacter pylori colonizes half of the world’s population as the dominant member of the gastric microbiota resulting in a lifelong chronic infection. Host responses toward the bacterium can result in asymptomatic, pathogenic or even favorable health outcomes; however, mechanisms underlying the dual role of H. pylori as a commensal versus pathogenic organism are not well characterized. Recent evidence suggests mononuclear phagocytes are largely involved in shaping dominant immunity during infection mediating the balance between host tolerance and succumbing to overt disease. We combined computational modeling, bioinformatics and experimental validation in order to investigate interactions between macrophages and intracellular H. pylori. Global transcriptomic analysis on bone marrow-derived macrophages (BMDM) in a gentamycin protection assay at six time points unveiled the presence of three sequential host response waves: an early transient regulatory gene module followed by sustained and late effector responses. Kinetic behaviors of pattern recognition receptors (PRRs) are linked to differential expression of spatiotemporal response waves and function to induce effector immunity through extracellular and intracellular detection of H. pylori. We report that bacterial interaction with the host intracellular environment caused significant suppression of regulatory NLRC3 and NLRX1 in a pattern inverse to early regulatory responses. To further delineate complex immune responses and pathway crosstalk between effector and regulatory PRRs, we built a computational model calibrated using time-series RNAseq data. Our validated computational hypotheses are that: 1) NLRX1 expression regulates bacterial burden in macrophages; and 2) early host response cytokines down-regulate NLRX1 expression through a negative feedback circuit. This paper applies modeling approaches to characterize the regulatory role of NLRX1 in mechanisms of host tolerance employed by macrophages to respond to and/or to co-exist with intracellular H. pylori. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Systems Modeling of Molecular Mechanisms Controlling Cytokine-driven CD4+ T Cell Differentiation and Phenotype Plasticity.
- Author
-
Carbo, Adria, Hontecillas, Raquel, Kronsteiner, Barbara, Viladomiu, Monica, Pedragosa, Mireia, Lu, Pinyi, Philipson, Casandra W., Hoops, Stefan, Marathe, Madhav, Eubank, Stephen, Bisset, Keith, Wendelsdorf, Katherine, Jarrah, Abdul, Mei, Yongguo, and Bassaganya-Riera, Josep
- Subjects
T cell differentiation ,MOLECULAR biology ,CYTOKINES ,PHENOTYPIC plasticity ,CELLULAR signal transduction ,PEROXISOME proliferator-activated receptors ,IMMUNE response - Abstract
Differentiation of CD4+ T cells into effector or regulatory phenotypes is tightly controlled by the cytokine milieu, complex intracellular signaling networks and numerous transcriptional regulators. We combined experimental approaches and computational modeling to investigate the mechanisms controlling differentiation and plasticity of CD4+ T cells in the gut of mice. Our computational model encompasses the major intracellular pathways involved in CD4+ T cell differentiation into T helper 1 (Th1), Th2, Th17 and induced regulatory T cells (iTreg). Our modeling efforts predicted a critical role for peroxisome proliferator-activated receptor gamma (PPARγ) in modulating plasticity between Th17 and iTreg cells. PPARγ regulates differentiation, activation and cytokine production, thereby controlling the induction of effector and regulatory responses, and is a promising therapeutic target for dysregulated immune responses and inflammation. Our modeling efforts predict that following PPARγ activation, Th17 cells undergo phenotype switch and become iTreg cells. This prediction was validated by results of adoptive transfer studies showing an increase of colonic iTreg and a decrease of Th17 cells in the gut mucosa of mice with colitis following pharmacological activation of PPARγ. Deletion of PPARγ in CD4+ T cells impaired mucosal iTreg and enhanced colitogenic Th17 responses in mice with CD4+ T cell-induced colitis. Thus, for the first time we provide novel molecular evidence in vivo demonstrating that PPARγ in addition to regulating CD4+ T cell differentiation also plays a major role controlling Th17 and iTreg plasticity in the gut mucosa. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. The Role of Peroxisome Proliferator-Activated Receptor γ in Immune Responses to Enteroaggregative Escherichia coli Infection.
- Author
-
Philipson, Casandra W., Bassaganya-Riera, Josep, Viladomiu, Monica, Pedragosa, Mireia, Guerrant, Richard L., Roche, James K., and Hontecillas, Raquel
- Subjects
- *
PEROXISOME proliferator-activated receptors , *ESCHERICHIA coli diseases , *IMMUNE response , *DIARRHEA , *IMMUNOSUPPRESSION , *GENE expression , *ANIMAL models in research - Abstract
Background: Enteroaggregative Escherichia coli (EAEC) is recognized as an emerging cause of persistent diarrhea and enteric disease worldwide. Mucosal immunity towards EAEC infections is incompletely understood due in part to the lack of appropriate animal models. This study presents a new mouse model and investigates the role of peroxisome proliferator-activated receptor gamma (PPARγ) in the modulation of host responses to EAEC in nourished and malnourished mice. Methods/Principal Findings: Wild-type and T cell-specific PPARγ null C57BL/6 mice were fed protein-deficient diets at weaning and challenged with 5×109cfu EAEC strain JM221 to measure colonic gene expression and immune responses to EAEC. Antigen-specific responses to E. coli antigens were measured in nourished and malnourished mice following infection and demonstrated the immunosuppressive effects of malnutrition at the cellular level. At the molecular level, both pharmacological blockade and deletion of PPARγ in T cells resulted in upregulation of TGF-β, IL-6, IL-17 and anti-microbial peptides, enhanced Th17 responses, fewer colonic lesions, faster clearance of EAEC, and improved recovery. The beneficial effects of PPARγ blockade on weight loss and EAEC clearance were abrogated by neutralizing IL-17 in vivo. Conclusions: Our studies provide in vivo evidence supporting the beneficial role of mucosal innate and effector T cell responses on EAEC burden and suggest pharmacological blockade of PPARγ as a novel therapeutic intervention for EAEC infection. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
13. Detection of Recombinant Rousettus Bat Coronavirus GCCDC1 in Lesser Dawn Bats (Eonycteris spelaea) in Singapore.
- Author
-
Paskey, Adrian C., Ng, Justin H. J., Rice, Gregory K., Chia, Wan Ni, Philipson, Casandra W., Foo, Randy J.H., Cer, Regina Z., Long, Kyle A., Lueder, Matthew R., Lim, Xiao Fang, Frey, Kenneth G., Hamilton, Theron, Anderson, Danielle E., Laing, Eric D., Mendenhall, Ian H., Smith, Gavin J., Wang, Lin-Fa, and Bishop-Lilly, Kimberly A.
- Subjects
COVID-19 pandemic ,CORONAVIRUSES ,BATS ,RECOMBINANT viruses - Abstract
Rousettus bat coronavirus GCCDC1 (RoBat-CoV GCCDC1) is a cross-family recombinant coronavirus that has previously only been reported in wild-caught bats in Yúnnan, China. We report the persistence of a related strain in a captive colony of lesser dawn bats captured in Singapore. Genomic evidence of the virus was detected using targeted enrichment sequencing, and further investigated using deeper, unbiased high throughput sequencing. RoBat-CoV GCCDC1 Singapore shared 96.52% similarity with RoBat-CoV GCCDC1 356 (NC_030886) at the nucleotide level, and had a high prevalence in the captive bat colony. It was detected at five out of six sampling time points across the course of 18 months. A partial segment 1 from an ancestral Pteropine orthoreovirus, p10, makes up the recombinant portion of the virus, which shares high similarity with previously reported RoBat-CoV GCCDC1 strains that were detected in Yúnnan, China. RoBat-CoV GCCDC1 is an intriguing, cross-family recombinant virus, with a geographical range that expands farther than was previously known. The discovery of RoBat-CoV GCCDC1 in Singapore indicates that this recombinant coronavirus exists in a broad geographical range, and can persist in bat colonies long-term. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Characterizing Phage Genomes for Therapeutic Applications.
- Author
-
Philipson, Casandra W., Voegtly, Logan J., Lueder, Matthew R., Long, Kyle A., Rice, Gregory K., Frey, Kenneth G., Biswas, Biswajit, Cer, Regina Z., Hamilton, Theron, and Bishop-Lilly, Kimberly A.
- Subjects
- *
VIRAL genetics , *BACTERIOPHAGES , *NUCLEOTIDE sequence , *MULTIDRUG resistance in bacteria - Abstract
Multi-drug resistance is increasing at alarming rates. The efficacy of phage therapy, treating bacterial infections with bacteriophages alone or in combination with traditional antibiotics, has been demonstrated in emergency cases in the United States and in other countries, however remains to be approved for wide-spread use in the US. One limiting factor is a lack of guidelines for assessing the genomic safety of phage candidates. We present the phage characterization workflow used by our team to generate data for submitting phages to the Federal Drug Administration (FDA) for authorized use. Essential analysis checkpoints and warnings are detailed for obtaining high-quality genomes, excluding undesirable candidates, rigorously assessing a phage genome for safety and evaluating sequencing contamination. This workflow has been developed in accordance with community standards for high-throughput sequencing of viral genomes as well as principles for ideal phages used for therapy. The feasibility and utility of the pipeline is demonstrated on two new phage genomes that meet all safety criteria. We propose these guidelines as a minimum standard for phages being submitted to the FDA for review as investigational new drug candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
15. Cooperation of Gastric Mononuclear Phagocytes with Helicobacter pylori during Colonization.
- Author
-
Viladomiu, Monica, Bassaganya-Riera, Josep, Tubau-Juni, Nuria, Kronsteiner, Barbara, Leber, Andrew, Philipson, Casandra W., Zoccoli-Rodriguez, Victoria, and Hontecillas, Raquel
- Subjects
- *
MACROPHAGES , *HELICOBACTER pylori , *COLONIZATION , *LIPOSOMES , *T cells - Abstract
Helicobacter pylori, the dominant member of the human gastric microbiota, elicits immunoregulatory responses implicated in protective versus pathological outcomes. To evaluate the role of macrophages during infection, we employed a system with a shifted proinflammatory macrophage phenotype by deleting PPARγ in myeloid cells and found a 5- to 10-fold decrease in gastric bacterial loads. Higher levels of colonization in wild-type mice were associated with increased presence of mononuclear phagocytes and in particular with the accumulation of CD11b+F4/80hiCD64+CX3CR1+ macrophages in the gastric lamina propria. Depletion of phagocytic cells by clodronate liposomes in wild-type mice resulted in a reduction of gastric H. pylori colonization compared with nontreated mice. PPARγ-deficient and macrophage-depleted mice presented decreased IL-10-mediated myeloid and T cell regulatory responses soon after infection. IL-10 neutralization during H. pylori infection led to increased IL-17-mediated responses and increased neutrophil accumulation at the gastric mucosa. In conclusion, we report the induction of IL-10-driven regulatory responses mediated by CD11b+F4/80hiCD64+CX3CR1+ mononuclear phagocytes that contribute to maintaining high levels of H. pylori loads in the stomach by modulating effector T cell responses at the gastric mucosa. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Notes from the Field: Early Identification of the SARS-CoV-2 Omicron BA.2.86 Variant by the Traveler-Based Genomic Surveillance Program - Dulles International Airport, August 2023.
- Author
-
Bart SM, Rothstein AP, Philipson CW, Smith TC, Simen BB, Tamin A, Atherton LJ, Harcourt JL, Taylor Walker A, Payne DC, Ernst ET, Morfino RC, Ruskey I, and Friedman CR
- Subjects
- Humans, Airports, Genomics, Risk Assessment, SARS-CoV-2 genetics, COVID-19
- Abstract
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Andrew P. Rothstein, Casandra W. Philipson, Birgitte B. Simen, and Robert C. Morfino own Ginkgo Bioworks employee stocks or restricted stock unit grants. Ezra T. Ernst owns XWELL employee stocks or restricted stock unit grants. No other potential conflicts of interest were disclosed.
- Published
- 2023
- Full Text
- View/download PDF
17. NLRX1 suppresses tumorigenesis and attenuates histiocytic sarcoma through the negative regulation of NF-κB signaling.
- Author
-
Coutermarsh-Ott S, Simmons A, Capria V, LeRoith T, Wilson JE, Heid B, Philipson CW, Qin Q, Hontecillas-Magarzo R, Bassaganya-Riera J, Ting JP, Dervisis N, and Allen IC
- Subjects
- Animals, Carcinogenesis, Disease Models, Animal, Female, Histiocytic Sarcoma genetics, Histiocytic Sarcoma pathology, Humans, Mice, Mice, Inbred C57BL, Mitochondrial Proteins genetics, NF-kappa B genetics, Signal Transduction, Histiocytic Sarcoma metabolism, Mitochondrial Proteins metabolism, NF-kappa B metabolism
- Abstract
Histiocytic sarcoma is an uncommon malignancy in both humans and veterinary species. Research exploring the pathogenesis of this disease is scarce; thus, diagnostic and therapeutic options for patients are limited. Recent publications have suggested a role for the NLR, NLRX1, in acting as a tumor suppressor. Based on these prior findings, we hypothesized that NLRX1 would function to inhibit tumorigenesis and thus the development of histiocytic sarcoma. To test this, we utilized Nlrx1-/- mice and a model of urethane-induced tumorigenesis. Nlrx1-/- mice exposed to urethane developed splenic histiocytic sarcoma that was associated with significant up-regulation of the NF-κB signaling pathway. Additionally, development of these tumors was also significantly associated with the increased regulation of genes associated with AKT signaling, cell death and autophagy. Together, these data show that NLRX1 suppresses tumorigenesis and reveals new genetic pathways involved in the pathobiology of histiocytic sarcoma., Competing Interests: The authors have no conflicts of interest to disclose.
- Published
- 2016
- Full Text
- View/download PDF
18. Lanthionine synthetase component C-like protein 2: a new drug target for inflammatory diseases and diabetes.
- Author
-
Lu P, Hontecillas R, Philipson CW, and Bassaganya-Riera J
- Subjects
- Abscisic Acid metabolism, Animals, Humans, Hypoglycemic Agents pharmacology, Inflammation metabolism, Membrane Proteins antagonists & inhibitors, Membrane Proteins genetics, Mice, Models, Molecular, Phosphate-Binding Proteins, Protein Conformation, Anti-Inflammatory Agents pharmacology, Inflammation drug therapy, Membrane Proteins chemistry, Membrane Proteins metabolism, Nuclear Proteins antagonists & inhibitors
- Abstract
Lanthionine synthetase component C-like protein 2 (LANCL2) is a member of the LANCL protein family, which is broadly expressed throughout the body. LANCL2 is the molecular target of abscisic acid (ABA), a compound with insulin-sensitizing and immune modulatory actions. LANCL2 is required for membrane binding and signaling of ABA in immune cells. Direct binding of ABA to LANCL2 was predicted in silico using molecular modeling approaches and validated experimentally using ligand-binding assays and kinetic surface plasmon resonance studies. The therapeutic potential of the LANCL2 pathway ranges from increasing cellular sensitivity to anticancer drugs, insulin-sensitizing effects and modulating immune and inflammatory responses in the context of immune-mediated and infectious diseases. A case for LANCL2-based drug discovery and development is also illustrated by the anti-inflammatory activity of novel LANCL2 ligands such as NSC61610 against inflammatory bowel disease and influenza-driven inflammation in mice. This review discusses the value of LANCL2 as a novel therapeutic target for the discovery and development of new classes of orally active drugs against chronic metabolic, immune-mediated and infectious diseases.
- Published
- 2014
- Full Text
- View/download PDF
19. The role of peroxisome proliferator-activated receptor γ in immune responses to enteroaggregative Escherichia coli infection.
- Author
-
Philipson CW, Bassaganya-Riera J, Viladomiu M, Pedragosa M, Guerrant RL, Roche JK, and Hontecillas R
- Subjects
- Anilides pharmacology, Animals, Antigens, Bacterial immunology, Bacterial Load genetics, Bacterial Load immunology, Body Weight drug effects, Cell Proliferation drug effects, Disease Progression, Epithelial Cells drug effects, Epithelial Cells immunology, Epithelial Cells metabolism, Epithelial Cells microbiology, Escherichia coli immunology, Escherichia coli Infections complications, Escherichia coli Infections metabolism, Gene Expression Regulation drug effects, Gene Expression Regulation immunology, Gene Knockout Techniques, Interleukin-17 metabolism, Intestinal Mucosa drug effects, Intestinal Mucosa immunology, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Malnutrition complications, Mice, Mice, Inbred C57BL, PPAR gamma antagonists & inhibitors, PPAR gamma deficiency, PPAR gamma genetics, T-Lymphocytes drug effects, T-Lymphocytes immunology, T-Lymphocytes metabolism, T-Lymphocytes microbiology, Time Factors, Escherichia coli physiology, Escherichia coli Infections immunology, PPAR gamma metabolism
- Abstract
Background: Enteroaggregative Escherichia coli (EAEC) is recognized as an emerging cause of persistent diarrhea and enteric disease worldwide. Mucosal immunity towards EAEC infections is incompletely understood due in part to the lack of appropriate animal models. This study presents a new mouse model and investigates the role of peroxisome proliferator-activated receptor gamma (PPARγ) in the modulation of host responses to EAEC in nourished and malnourished mice., Methods/principal Findings: Wild-type and T cell-specific PPARγ null C57BL/6 mice were fed protein-deficient diets at weaning and challenged with 5×10(9)cfu EAEC strain JM221 to measure colonic gene expression and immune responses to EAEC. Antigen-specific responses to E. coli antigens were measured in nourished and malnourished mice following infection and demonstrated the immunosuppressive effects of malnutrition at the cellular level. At the molecular level, both pharmacological blockade and deletion of PPARγ in T cells resulted in upregulation of TGF-β, IL-6, IL-17 and anti-microbial peptides, enhanced Th17 responses, fewer colonic lesions, faster clearance of EAEC, and improved recovery. The beneficial effects of PPARγ blockade on weight loss and EAEC clearance were abrogated by neutralizing IL-17 in vivo., Conclusions: Our studies provide in vivo evidence supporting the beneficial role of mucosal innate and effector T cell responses on EAEC burden and suggest pharmacological blockade of PPARγ as a novel therapeutic intervention for EAEC infection.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.